

LESCARDEN INC.

For Immediate Press Release

Lescarden Enters Into Distribution Agreement for Catrix Wound Dressing in the United Kingdom

New York, NY December 3, 2008 Lescarden, Inc. (LCAR:OB) announced today that it had entered into a distribution agreement with Cranage Healthcare Ltd. to market Lescarden's proprietary CATRIX® WOUND DRESSING in the United Kingdom and Ireland. Regulatory marketing approvals and product reimbursement arrangements are being secured, and it is anticipated that product launch will commence in the first quarter of 2009.

William Luther, Lescarden's President, said, "We are pleased with this new distribution agreement, which should enable us to make a significant penetration, for the first time, into one of the most important European markets for our products." The Catrix Wound Dressing is currently being distributed in Spain by Smith and Nephew, Inc.

Cranage Healthcare Ltd. is a rapidly growing privately held firm based in Congleton, England. The company has built an international reputation for providing high value, critical care products to hospitals, burn centers, plastic surgeons and dermatologists in the UK and Europe.

With twenty years of industry experience, Cranage is able to add value to brands through its own direct sales infrastructure and through a network of overseas contacts. To date, the company has successfully launched two products that have taken significant market share from the competition.

Lescarden's Catrix Wound Dressing utilizes bovine cartilage that has been refined into a fine, white powder. It has been shown in extensive clinical testing to be an effective aid in the healing of wounds that are resistant to the healing process. The product has been approved by the United States FDA for the management of first and second degree burns as well as decubitus ulcers, venous stasis and diabetic ulcers and post-radiation dermatitis.

In a study published in *Cosmetic Dermatology* in August 2008, the burn-healing capability of Catrix Wound Dressing was evaluated in the treatment of 41 pediatric patients with second and third degree burns that were unresponsive to conventional therapy. When treated with Catrix the children's wounds all healed completely with no residual scarring. The study concluded that the Catrix product offers burn specialists a viable non-surgical alternative to skin grafting in such situations.

Lescarden, Inc. is a biotechnology company dedicated to the development of natural, biologic therapies for the chronic wound care, dermatology and osteoarthritis markets. For more information please contact the Company at 212- 687-1050 or visit www.catrix.com.